---
document_datetime: 2025-12-02 05:03:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria.html
document_name: vaxzevria.html
version: success
processing_time: 0.3075654
conversion_datetime: 2025-12-24 18:28:58.72049
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

[RSS](/en/individual-human-medicine.xml/67417)

##### Withdrawn

This medicine's authorisation has been withdrawn

COVID-19 Vaccine (ChAdOx1-S [recombinant]) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Safety updates](#safety-updates)
- [News on Vaxzevria (previously COVID-19 Vaccine AstraZeneca)](#news-on)
- [Signal assessment reports](#signal-assessment-reports-1610)
- [Related information on Vaxzevria](#related-information-on-vaxzevria-929)
- [External links](#external-links-931)
- [More information on Vaxzevria (previously COVID-19 Vaccine AstraZeneca)](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria (COVID 19 Vaccine (ChAdOx1 S [recombinant])) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vaxzevria was granted conditional marketing authorisation in the EU on 29 January 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorization, valid for 5 years, on 31 October 2022.

The European Public Assessment Report (EPAR) for Vaxzevria is updated to indicate that the marketing authorisation is no longer valid.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Medicine overview

Reference Number: EMA/609262/2021

English (EN) (314.66 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 07/05/2024

[View](/en/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-277)

български (BG) (440.14 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/bg/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_bg.pdf)

español (ES) (325.94 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/es/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_es.pdf)

čeština (CS) (407.92 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/cs/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_cs.pdf)

dansk (DA) (313.75 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/da/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_da.pdf)

Deutsch (DE) (341.04 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/de/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_de.pdf)

eesti keel (ET) (285.3 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/et/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_et.pdf)

ελληνικά (EL) (445.33 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/el/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_el.pdf)

français (FR) (334.3 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fr/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_fr.pdf)

hrvatski (HR) (372.28 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hr/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_hr.pdf)

italiano (IT) (319.96 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/it/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (392.79 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lv/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (386.12 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lt/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_lt.pdf)

magyar (HU) (361.87 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hu/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_hu.pdf)

Malti (MT) (415.3 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/mt/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_mt.pdf)

Nederlands (NL) (333.96 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/nl/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_nl.pdf)

polski (PL) (394.94 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pl/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_pl.pdf)

português (PT) (322.48 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pt/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_pt.pdf)

română (RO) (397.61 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/ro/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_ro.pdf)

slovenčina (SK) (405.97 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sk/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_sk.pdf)

slovenščina (SL) (396.69 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sl/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_sl.pdf)

Suomi (FI) (315.53 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fi/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_fi.pdf)

svenska (SV) (311.37 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sv/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_sv.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Risk-management-plan

English (EN) (3.02 MB - PDF)

**First published:** 18/02/2021

**Last updated:** 07/05/2024

[View](/en/documents/rmp/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-risk-management-plan_en.pdf)

## Product information

Vaxzevria : EPAR - Product information

English (EN) (709.52 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 07/05/2024

[View](/en/documents/product-information/vaxzevria-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-775)

български (BG) (831.75 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/bg/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_bg.pdf)

español (ES) (1.36 MB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/es/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_es.pdf)

čeština (CS) (781.7 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/cs/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_cs.pdf)

dansk (DA) (738.48 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/da/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_da.pdf)

Deutsch (DE) (826.38 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/de/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_de.pdf)

eesti keel (ET) (714.13 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/et/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_et.pdf)

ελληνικά (EL) (933.6 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/el/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_el.pdf)

français (FR) (841.85 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fr/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_fr.pdf)

hrvatski (HR) (767.67 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hr/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_hr.pdf)

íslenska (IS) (735.22 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/is/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_is.pdf)

italiano (IT) (849.88 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/it/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_it.pdf)

latviešu valoda (LV) (731.52 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lv/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_lv.pdf)

lietuvių kalba (LT) (675.84 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lt/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_lt.pdf)

magyar (HU) (805.83 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hu/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_hu.pdf)

Malti (MT) (891.16 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/mt/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_mt.pdf)

Nederlands (NL) (787.89 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/nl/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_nl.pdf)

norsk (NO) (779.45 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/no/documents/product-information/vaxzevria-epar-product-information_no.pdf)

polski (PL) (779.29 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pl/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_pl.pdf)

português (PT) (820.98 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pt/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_pt.pdf)

română (RO) (799.55 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/ro/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_ro.pdf)

slovenčina (SK) (760.59 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sk/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_sk.pdf)

slovenščina (SL) (723.08 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sl/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_sl.pdf)

Suomi (FI) (734.28 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fi/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_fi.pdf)

svenska (SV) (732.61 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sv/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0096 07/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - All authorised presentation

English (EN) (57.61 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 07/05/2024

[View](/en/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_en.pdf)

[Other languages (24)](#file-language-dropdown-853)

български (BG) (67.56 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/bg/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_bg.pdf)

español (ES) (62.29 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/es/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_es.pdf)

čeština (CS) (59.8 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/cs/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_cs.pdf)

dansk (DA) (66.17 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/da/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_da.pdf)

Deutsch (DE) (59.72 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/de/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_de.pdf)

eesti keel (ET) (56.96 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/et/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_et.pdf)

ελληνικά (EL) (82.04 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/el/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_el.pdf)

français (FR) (58.29 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fr/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_fr.pdf)

hrvatski (HR) (69.55 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hr/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_hr.pdf)

íslenska (IS) (61.74 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/is/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_is.pdf)

italiano (IT) (60.42 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/it/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_it.pdf)

latviešu valoda (LV) (59.7 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lv/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_lv.pdf)

lietuvių kalba (LT) (74.75 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/lt/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_lt.pdf)

magyar (HU) (64.46 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/hu/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_hu.pdf)

Malti (MT) (72.83 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/mt/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_mt.pdf)

Nederlands (NL) (57.23 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/nl/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_nl.pdf)

norsk (NO) (58.52 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/no/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_no.pdf)

polski (PL) (64.17 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pl/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_pl.pdf)

português (PT) (65.3 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/pt/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_pt.pdf)

română (RO) (60.7 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/ro/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_ro.pdf)

slovenčina (SK) (59.79 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sk/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_sk.pdf)

slovenščina (SL) (57.49 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sl/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_sl.pdf)

Suomi (FI) (57 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/fi/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_fi.pdf)

svenska (SV) (58.72 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

07/05/2024

[View](/sv/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_sv.pdf)

## Product details

Name of medicine Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Active substance ChAdOx1-SARS-COV-2 International non-proprietary name (INN) or common name COVID-19 Vaccine (ChAdOx1-S [recombinant]) Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J07BN02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005675 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 29/01/2021 Marketing authorisation issued 29/01/2021 Withdrawal of marketing authorisation 27/03/2024 Revision 32

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.13 MB - PDF)

**First published:** 23/03/2021

**Last updated:** 07/05/2024

[View](/en/documents/procedural-steps-after/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-PSUSA-00010912-202212 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/317895/2023

English (EN) (713.83 KB - PDF)

**First published:** 21/09/2023

**Last updated:** 07/05/2024

[View](/en/documents/scientific-conclusion/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-psusa-00010912-202212-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-PSUSA-00010912-202206: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/38839/2023

English (EN) (701.32 KB - PDF)

**First published:** 20/03/2023

**Last updated:** 07/05/2024

[View](/en/documents/scientific-conclusion/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-psusa-00010912-202206-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-5675-R-0079 : EPAR - Assessment report - Renewal

Adopted

Reference Number: EMA/865685/2022

English (EN) (1.3 MB - PDF)

**First published:** 17/11/2022

**Last updated:** 07/05/2024

[View](/en/documents/variation-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-5675-r-0079-epar-assessment-report-renewal_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-PSUSA-00010912-202112 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/666408/2022

English (EN) (722.66 KB - PDF)

**First published:** 12/08/2022

**Last updated:** 07/05/2024

[View](/en/documents/scientific-conclusion/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-psusa-00010912-202112-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-5675-II-0052 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/351687/2022

English (EN) (10.41 MB - PDF)

**First published:** 04/08/2022

**Last updated:** 07/05/2024

[View](/en/documents/variation-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-5675-ii-0052-epar-assessment-report-variation_en.pdf)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)-H-C-5675-R-0037 : EPAR - Assessment report - Renewal

Adopted

Reference Number: EMA/622071/2021

English (EN) (1.41 MB - PDF)

**First published:** 18/11/2021

**Last updated:** 07/05/2024

[View](/en/documents/variation-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-h-c-5675-r-0037-epar-assessment-report-renewal_en.pdf)

## Initial marketing authorisation documents

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Public assessment report

Adopted

Reference Number: EMA/94907/2021

English (EN) (9.96 MB - PDF)

**First published:** 18/02/2021

**Last updated:** 07/05/2024

[View](/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for COVID-19 Vaccine AstraZeneca

Adopted

Reference Number: EMA/57617/2021

English (EN) (269.64 KB - PDF)

**First published:** 29/01/2021

**Last updated:** 07/05/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-astrazeneca_en.pdf)

#### Safety updates

Vaxzevria: Periodic safety update report assessment 29 December 2022 to 28 December 2023

Adopted

English (EN) (15.79 MB - PDF)

**First published:** 22/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-december-2022-28-december-2023_en.pdf)

COVID-19 vaccines - Safety update: 14 July 2022

Adopted

Reference Number: Rev. 1

English (EN) (263.34 KB - PDF)

**First published:** 14/07/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 September 2022

Adopted

English (EN) (257.73 KB - PDF)

**First published:** 08/09/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-september-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 March 2022

Adopted

English (EN) (237.65 KB - PDF)

**First published:** 17/03/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-march-2022_en.pdf)

COVID-19 vaccines - Safety update: 6 October 2022

Adopted

English (EN) (237.46 KB - PDF)

**First published:** 06/10/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-6-october-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 December 2022

Adopted

English (EN) (239.73 KB - PDF)

**First published:** 08/12/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf)

COVID-19 vaccines - Safety update: 10 November 2022

Adopted

English (EN) (254.94 KB - PDF)

**First published:** 10/11/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf)

COVID-19 vaccines - Safety update: 12 May 2022

Adopted

English (EN) (214.22 KB - PDF)

**First published:** 12/05/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-12-may-2022_en.pdf)

COVID-19 vaccines - Safety update: 13 April 2022

Adopted

English (EN) (228.5 KB - PDF)

**First published:** 13/04/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-13-april-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 February 2022

Adopted

English (EN) (226.15 KB - PDF)

**First published:** 17/02/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-february-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 June 2022

Adopted

English (EN) (249.16 KB - PDF)

**First published:** 17/06/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-june-2022_en.pdf)

COVID-19 vaccines - Safety update: 20 January 2022

Adopted

English (EN) (251.15 KB - PDF)

**First published:** 20/01/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-20-january-2022_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 8 September 2021

Adopted

English (EN) (492.14 KB - PDF)

**First published:** 08/09/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 9 December 2021

Adopted

English (EN) (301.05 KB - PDF)

**First published:** 09/12/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-9-december-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 August 2021

Adopted

English (EN) (280.1 KB - PDF)

**First published:** 11/08/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-august-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 November 2021

Adopted

English (EN) (333.55 KB - PDF)

**First published:** 11/11/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 14 April 2021

Adopted

English (EN) (340.14 KB - PDF)

**First published:** 16/04/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 14 July 2021

Adopted

English (EN) (347.15 KB - PDF)

**First published:** 14/07/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 18 June 2021

Adopted

English (EN) (489.91 KB - PDF)

**First published:** 18/06/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-18-june-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 21 May 2021

Adopted

English (EN) (264.25 KB - PDF)

**First published:** 21/05/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-21-may-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 29 March 2021

Adopted

English (EN) (413.69 KB - PDF)

**First published:** 30/03/2021

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf)

Vaxzevria: Periodic safety update report assessment 29 December 2021 to 28 June 2022

Adopted

English (EN) (39.56 MB - PDF)

**First published:** 18/12/2023

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-december-2021-28-june-2022_en.pdf)

Vaxzevria: Periodic safety update report assessment 29 June 2022 to 28 December 2022

Adopted

English (EN) (15.04 MB - PDF)

**First published:** 21/12/2023

**Last updated:** 07/05/2024

[View](/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-june-2022-28-december-2022_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 6 October 2021

Adopted

English (EN) (115.75 KB - PDF)

**First published:** 06/10/2021

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-6-october-2021_en.pdf)

COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 May 2021

Adopted

English (EN) (87.31 KB - PDF)

**First published:** 12/05/2021

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-may-2021_en.pdf)

#### News on Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

[Increase in manufacturing capacity for Vaxzevria (previously COVID-19 Vaccine AstraZeneca)](/en/news/increase-manufacturing-capacity-vaxzevria-previously-covid-19-vaccine-astrazeneca) 24/01/2022

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022) 14/01/2022

[Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca](/en/news/increase-manufacturing-capacity-covid-19-vaccine-astrazeneca) 01/12/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-september-2021) 01/10/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5 August 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-august-2021) 06/08/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021) 11/06/2021

[Vaxzevria: EMA advises against use in people with history of capillary leak syndrome](/en/news/vaxzevria-ema-advises-against-use-people-history-capillary-leak-syndrome) 11/06/2021

[COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis](/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis) 11/06/2021

[EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome](/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia-syndrome) 07/06/2021

[Vaxzevria: further advice on blood clots and low blood platelets](/en/news/vaxzevria-further-advice-blood-clots-low-blood-platelets) 21/05/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021) 07/05/2021

[AstraZeneca's COVID-19 vaccine: benefits and risks in context](/en/news/astrazenecas-covid-19-vaccine-benefits-and-risks-context) 23/04/2021

[AstraZeneca's COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets](/en/news/astrazenecas-covid-19-vaccine-ema-provide-further-context-risk-very-rare-blood-clots-low-blood-platelets) 14/04/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021) 09/04/2021

[AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets](/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets) 07/04/2021

[AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues](/en/news/astrazeneca-covid-19-vaccine-review-very-rare-cases-unusual-blood-clots-continues) 31/03/2021

[Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna](/en/news/increase-vaccine-manufacturing-capacity-supply-covid-19-vaccines-astrazeneca-biontech-pfizer-moderna) 26/03/2021

[COVID-19 Vaccine AstraZeneca - Update on ongoing evaluation of blood clot cases](/en/news/covid-19-vaccine-astrazeneca-update-ongoing-evaluation-blood-clot-cases) 25/03/2021

[COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets](/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots-low-blood-platelets) 18/03/2021

[Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues](/en/news/investigation-covid-19-vaccine-astrazeneca-thromboembolic-events-continues) 16/03/2021

[EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events - further update](/en/news/emas-safety-committee-continues-investigation-covid-19-vaccine-astrazeneca-thromboembolic-events-further-update) 15/03/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-march-2021) 12/03/2021

[COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - Update](/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits-currently-still-outweigh-risks-update) 11/03/2021

[COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria](/en/news/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria) 10/03/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

[EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU](/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu) 29/01/2021

[EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca](/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-astrazeneca) 12/01/2021

[Update on rolling review of AstraZeneca's COVID-19 vaccine](/en/news/update-rolling-review-astrazenecas-covid-19-vaccine) 30/12/2020

[EMA starts first rolling review of a COVID-19 vaccine in the EU](/en/news/ema-starts-first-rolling-review-covid-19-vaccine-eu) 01/10/2020

#### Signal assessment reports

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) - Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines)

Adopted

Reference Number: EMA/205598/2021

English (EN) (3.5 MB - PDF)

**First published:** 13/04/2021

**Last updated:** 07/05/2024

[View](/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-vaxzevria-previously-covid-19-vaccine-astrazeneca-other-viral-vaccines_en.pdf)

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVID-19 Vaccine AstraZeneca (Other viral vaccines)

Adopted

Reference Number: EMA/PRAC/157045/2021

English (EN) (1.87 MB - PDF)

**First published:** 31/03/2021

**Last updated:** 07/05/2024

[View](/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid-19-vaccine-astrazeneca-other-viral-vaccines_en.pdf)

#### Related information on Vaxzevria

- [Article-5(3)-opinion: Use of Vaxzevria to prevent COVID-19](/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/article-53-opinions-any-scientific-matter-human-medicines)

#### External links

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home) (login required)

#### More information on Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

- [EMEA-002862-PIP01-20-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002862-pip01-20-m04)
- [Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca)
- [Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-0)
- [Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-1)
- [Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-2)
- [Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-3)
- [A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19) - post-authorisation study](https://catalogues.ema.europa.eu/study/48711)
- [id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe - post-authorisation study](https://catalogues.ema.europa.eu/study/49374)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Healthcare worker cohort - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000094)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS), Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000095)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Vaccine effectiveness and the impact of COVID-19 vaccines through routinely collected exposure and outcome data using health registries - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000101)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Vaccine effectiveness hospital admission with Severe Acute Respiratory Infection - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000099)
- [Incidence rates of pemphigus and pemphigoid following COVID-19 vaccines - post-authorisation study](https://catalogues.ema.europa.eu/study/50716)
- [Effectiveness of monovalent XBB.1.5-containing Covid-19 mRNA vaccines in the Nordic countries - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000043)
- [Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain) - post-authorisation study](https://catalogues.ema.europa.eu/study/42710)

**This page was last updated on** 22/08/2024

## Share this page

[Back to top](#main-content)